1
|
Narang GL, Rojanasarot S, Cutone B, Humphreys MR. Is Race Associated with the Surgical Treatment for Benign Prostatic Hyperplasia? An Analysis of 30,000 Medicare Lives. J Racial Ethn Health Disparities 2024; 11:528-534. [PMID: 37095287 PMCID: PMC10781854 DOI: 10.1007/s40615-023-01538-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Revised: 02/10/2023] [Accepted: 02/13/2023] [Indexed: 04/26/2023]
Abstract
BACKGROUNDS With an increased prevalence and burden of benign prostatic hyperplasia (BPH), effective and equitable treatment is a priority. Limited data exist evaluating treatment disparities for patients with BPH by race. This study examined the association between race and BPH surgical treatment rates among Medicare beneficiaries. METHODS Medicare claims data were used to identify men newly diagnosed with BPH from January 1, 2010 through December 31, 2018. Patients were followed until their first BPH surgery, a diagnosis of prostate/bladder cancer, termination of Medicare enrollment, death, or end of study. Cox proportional hazards regression compared the likelihood of BPH surgery between men of different races (White vs. Black, Indigenous, and People of Color (BIPOC)), controlling for patients' geographical region, Charlson comorbidity score, and baseline comorbidities. RESULTS The study included 31,699 patients (13.7% BIPOC). BIPOC men had significantly lower BPH surgery rates (9.5% BIPOC vs. 13.4% White; p=0.02). BIPOC race was associated with a 19% lower likelihood of receiving BPH surgery than White race (HR, 0.81; 95% CI 0.70, 0.94). Transurethral resection of the prostate was the most common surgery for both groups (49.4% Whites vs. 56.8% BIPOC; p=0.052). A higher proportion of BIPOC men underwent procedures in inpatient settings compared to White men (18.2% vs. 9.8%; p<0.001). CONCLUSIONS Among a cohort of Medicare beneficiaries with BPH, there were notable treatment disparities by race. BIPOC men had lower rates of surgery than White men and were more likely to undergo procedures in the inpatient setting. Improving patient access to outpatient BPH surgical procedures may help address treatment disparities.
Collapse
|
2
|
Anezaki H, Endo F, Swan G, Takashima K, Rojanasarot S. Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan's public healthcare system. J Med Econ 2024; 27:554-565. [PMID: 38466193 DOI: 10.1080/13696998.2024.2327920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Accepted: 02/29/2024] [Indexed: 03/12/2024]
Abstract
AIMS Benign prostatic hyperplasia (BPH) represents a significant public health issue in Japan. This study evaluated the lifetime cost-effectiveness of water vapor energy therapy (WAVE) versus prostatic urethral lift (PUL) for men with moderate-to-severe BPH from a public healthcare payer's perspective in Japan. MATERIALS AND METHODS A decision analytic model compared WAVE to PUL among males in Japan. Clinical effectiveness and adverse event (AE) inputs were obtained from a systematic literature review. Resource utilization and cost inputs were derived from the Medical Data Vision database and medical service fee national data in Japan. Experts reviewed and validated model input parameters. One-way and probabilistic sensitivity analyses were conducted to determine how changes in the values of uncertain parameters affect the model results. RESULTS Throughout patients' lifetimes, WAVE was associated with higher quality-adjusted life years (0.920 vs. 0.911 year 1; 15.564 vs. 15.388 lifetime) and lower total costs (¥734,134 vs. ¥888,110 year 1; ¥961,595 vs. ¥1,429,458 lifetime) compared to PUL, indicating that WAVE is a more effective and less costly (i.e. dominant) treatment strategy across all time horizons. Lifetime cost-savings for the Japanese healthcare system per patient treated with WAVE instead of PUL were ¥467,863. The 32.7% cost difference between WAVE and PUL was predominantly driven by lower WAVE surgical retreatment rates (4.9% vs. 19.2% for WAVE vs PUL, respectively, at 5 years) and AE rates (hematuria 11.8% vs. 25.7%, dysuria 16.9% vs. 34.3%, pelvic pain 2.9% vs. 17.9%, and urinary incontinence 0.4% vs. 1.3% for WAVE vs PUL, respectively, at 3 months). Model findings were robust to changes in parameter input values. LIMITATIONS The model represents a simplification of complex factors involved in resource allocation decision-making. CONCLUSIONS Driven by lower retreatment and AE rates, WAVE was a cost-effective and cost-saving treatment for moderate-to-severe BPH in Japan compared to PUL, providing better outcomes at lower costs to the healthcare system.
Collapse
Affiliation(s)
- Hisataka Anezaki
- Field of Artificial Intelligence and Digital Health Science, Graduate School of Medicine, Kobe University, Kobe, Japan
| | | | - Georgia Swan
- Boston Scientific, Asia Pacific, Singapore, Singapore
| | | | | |
Collapse
|
3
|
Efficacy and Safety of Common Ingredients in Aphrodisiacs Used for Erectile Dysfunction: A Review. Sex Med Rev 2020; 8:431-442. [PMID: 32139335 DOI: 10.1016/j.sxmr.2020.01.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 01/06/2020] [Accepted: 01/14/2020] [Indexed: 12/18/2022]
Abstract
INTRODUCTION Erectile dysfunction (ED) is the inability to attain or sustain an erection for sexual intercourse. Affected men endorse difficulties with intimacy and feelings of guilt and shame. Although medical treatments are available, patients are reluctant to discuss ED with physicians and often use dietary supplements to attempt to treat their ED. As such, there is a need to better understand the effects of ingredients used in nutraceuticals for ED treatment. OBJECTIVES To summarize the literature on the efficacy and safety of the most common ingredients used in ED supplements. METHODS 10 of the most common ingredients in ED supplements were reviewed using PubMed-indexed literature to assess their efficacy and safety in treating ED. Key findings were summarized to include historical use, active ingredients, prior animal studies, human studies, and toxicity. RESULTS Nutraceuticals used in ED treatment include a variety of ingredients. Although L-arginine is a safe supplement with clinical data supporting improved erectile function, limited data exist on the efficacy of other ingredients in the treatment of ED. CONCLUSION Despite the growing use of supplements for treatment of sexual dysfunction, ED supplements remain poorly studied, with limited data demonstrating efficacy of individual ingredients. Further study is required to definitively determine the efficacy of nutraceuticals in ED treatment. Srivatsav A, Balasubramanian A, Pathak UI, et al. Efficacy and Safety of Common Ingredients in Aphrodisiacs Used for Erectile Dysfunction: A Review. J Sex Med 2020;8:431-442.
Collapse
|
4
|
Wu G, Liu J, Yue X. Prediction of drug-disease associations based on ensemble meta paths and singular value decomposition. BMC Bioinformatics 2019; 20:134. [PMID: 30925858 PMCID: PMC6439991 DOI: 10.1186/s12859-019-2644-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background In the field of drug repositioning, it is assumed that similar drugs may treat similar diseases, therefore many existing computational methods need to compute the similarities of drugs and diseases. However, the calculation of similarity depends on the adopted measure and the available features, which may lead that the similarity scores vary dramatically from one to another, and it will not work when facing the incomplete data. Besides, supervised learning based methods usually need both positive and negative samples to train the prediction models, whereas in drug-disease pairs data there are only some verified interactions (positive samples) and a lot of unlabeled pairs. To train the models, many methods simply treat the unlabeled samples as negative ones, which may introduce artificial noises. Herein, we propose a method to predict drug-disease associations without the need of similarity information, and select more likely negative samples. Results In the proposed EMP-SVD (Ensemble Meta Paths and Singular Value Decomposition), we introduce five meta paths corresponding to different kinds of interaction data, and for each meta path we generate a commuting matrix. Every matrix is factorized into two low rank matrices by SVD which are used for the latent features of drugs and diseases respectively. The features are combined to represent drug-disease pairs. We build a base classifier via Random Forest for each meta path and five base classifiers are combined as the final ensemble classifier. In order to train out a more reliable prediction model, we select more likely negative ones from unlabeled samples under the assumption that non-associated drug and disease pair have no common interacted proteins. The experiments have shown that the proposed EMP-SVD method outperforms several state-of-the-art approaches. Case studies by literature investigation have found that the proposed EMP-SVD can mine out many drug-disease associations, which implies the practicality of EMP-SVD. Conclusions The proposed EMP-SVD can integrate the interaction data among drugs, proteins and diseases, and predict the drug-disease associations without the need of similarity information. At the same time, the strategy of selecting more reliable negative samples will benefit the prediction.
Collapse
Affiliation(s)
- Guangsheng Wu
- School of Computer Science, Wuhan University, Wuhan, 430072, People's Republic of China
| | - Juan Liu
- School of Computer Science, Wuhan University, Wuhan, 430072, People's Republic of China. .,Suzhou Institute of Wuhan University, Suzhou, 215123, People's Republic of China.
| | - Xiang Yue
- School of Computer Science, Wuhan University, Wuhan, 430072, People's Republic of China.,Department of Computer Science and Engineering, The Ohio State University, Ohio, 43210, USA
| |
Collapse
|
5
|
Yu Z, Li J, Li Z, Hou R. Photoselective Vaporization of the Prostate and Simultaneous Suprapubic Cystostomy for the Treatment of Benign Prostatic Hyperplasia in Patients with Mild to Severe Detrusor Underactivity. Urol Int 2015; 95:269-75. [DOI: 10.1159/000434688] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Accepted: 06/01/2015] [Indexed: 11/19/2022]
Abstract
Introduction: This study investigated the clinical efficacy and safety of photoselective vaporization of the prostate (PVP) and simultaneous suprapubic cystostomy for benign prostatic hyperplasia (BPH) in patients with mild to severe detrusor underactivity (DU). Subjects and Methods: Seventy-eight patients with BPH were divided into 3 groups according to the severity of DU: mild DU group, moderate DU group and severe DU group. The preoperative and postoperative data, including the detrusor pressure at maximum flow (Pdetmax), bladder compliance, maximum urinary flow (Qmax), postvoid residual urine (PVR) values, International Prostate Symptom Score (IPSS) and quality of life (QoL) were evaluated. Results: The therapeutic effectiveness including cure and improvement in mild and moderate DU group was significantly higher than that of the severe group. Compared to the preoperative values, Pdetmax, bladder compliance, Qmax, PVR, IPSS and QoL scores at 12 months postoperatively had significantly improved. In addition, the above parameters at 12 months postoperatively in the mild or moderate DU group had significant difference compared to the severe DU group. Conclusion: PVP and simultaneous suprapubic cystostomy seem to be an appropriate treatment modality in BPH patients with mild and/or moderate DU as well as in patients with severe DU and slightly reduced bladder compliance.
Collapse
|
6
|
Karsono AH, Tandrasasmita OM, Tjandrawinata RR. Molecular effects of bioactive fraction of Curcuma mangga (DLBS4847) as a downregulator of 5α-reductase activity pathways in prostatic epithelial cells. Cancer Manag Res 2014; 6:267-78. [PMID: 24944518 PMCID: PMC4057330 DOI: 10.2147/cmar.s61111] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
DLBS4847 is a standardized bioactive fraction of Curcuma mangga. In this study, we used prostate cancer (PC)-3 as the cell line to study the effects of DLBS4847 on prostatic cell viability, as well as related molecular changes associated with the decreased cell number. The observation revealed that DLBS4847 inhibited the growth of PC3 cells through downregulation of the 5α-reductase (5AR) pathway. At the transcription level, 5AR1 and androgen-receptor gene expressions were downregulated in a dose-dependent manner. Furthermore, 5AR-1 and dihydrotestosterone expression were also downregulated at the protein level. A microarray study was also performed to see the effects of DLBS4847 on differential gene expressions in prostate cancer 3 cells. Among others, DLBS4847 downregulated genes related to prostate growth and hypertrophy. Our results suggested that DLBS4847 could potentially become an alternative treatment for prostate disorders, such as benign prostatic hyperplasia. In this regard, DLBS4847 exerts its growth inhibition partially through downregulation of the 5AR pathway.
Collapse
Affiliation(s)
- Agung Heru Karsono
- Section of Molecular Pharmacology, Research Innovation and Invention, Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Cikarang, Indonesia
| | - Olivia Mayasari Tandrasasmita
- Section of Molecular Pharmacology, Research Innovation and Invention, Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Cikarang, Indonesia
| | - Raymond R Tjandrawinata
- Section of Molecular Pharmacology, Research Innovation and Invention, Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Cikarang, Indonesia
| |
Collapse
|
7
|
Les inhibiteurs de la phosphodiestérase de type 5 : une révolution dans le traitement des symptômes du bas appareil urinaire? Basic Clin Androl 2012. [DOI: 10.1007/s12610-012-0172-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Résumé
Contexte
L’incidence des symptômes du bas appareil urinaire (SBAU) liés à une hypertrophie bénigne de prostate (HBP) augmente avec l’âge puisqu’ils touchent 50 % des patients âgés de plus de 50 ans et 90 % de ceux âgés de plus de 80 ans. La prévalence et la sévérité de la dysfonction érectile (DE) augmentent également avec l’âge. Sa prévalence est évaluée à 31,6 % dans une population générale d’adultes âgés de plus de 40 ans. Les SBAU comme la DE altèrent de façon significative la qualité de vie (QdV) des patients et de leur partenaire. Plusieurs études ont montré que les SBAU constituent un facteur de risque de DE indépendant de l’âge et des autres comorbidités. La sévérité des SBAU est corrélée à celle de la DE. Les hypothèses physiopathologiques pour expliquer le lien entre SBAU et DE sont : une augmentation du tonus sympathique, une altération du système NO/cGMP, une altération du système rho-kinase et une athéromatose pelvienne.
Objectif
Évaluer les résultats et comprendre le mécanisme d’action de l’administration d’un inhibiteur de la phosphodiestérase de type 5 (IPDE 5) sur les SBAU liés à une HBP.
Matériels et méthodes
Une revue de la littérature a été réalisée à partir des articles originaux et des articles de synthèse déjà disponibles, sélectionnés par le moteur de recherche Pubmed de la National Library of Medecine. Les mots clés utilisés pour cette recherche ont été : benign prostatic hyperplasia; cyclic nucleotide phosphodiesterase type 5; LUTS; erectile dysfunction.
Résultats
Cette revue de la littérature montre que l’administration d’un inhibiteur de la phosphodiestérase de type 5 améliore les SBAU de manière significative dans 12 essais cliniques randomisés, avec un bénéfice également sur la DE et l’absence d’effets secondaires indésirables graves rapportés.
Conclusion
Le traitement des SBAU par les IPDEs 5 semble très prometteur, même s’il ne dispose pas d’une AMM dans cette indication en France. Récemment, le tadalafil à la posologie de 5 mg a été approuvé aux États-Unis par la FDA dans les troubles mictionnels liés à l’HBP, avec ou sans DE.
Collapse
|
8
|
|
9
|
[Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article]. Prog Urol 2010; 20:616-26. [PMID: 20951929 DOI: 10.1016/j.purol.2010.07.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2010] [Revised: 06/22/2010] [Accepted: 07/20/2010] [Indexed: 11/23/2022]
Abstract
CONTEXT In aging males, there is an increased prevalence of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) whose affect significantly their quality of life. LUTS would represent for ED an independent risk factor. Some treatment of LUTS have undesirable effects on the erectile function. The phosphodiesterase type 5 inhibitors (IPDE 5) revolutionized the treatment of ED. Several recent clinical studies evaluated the effect daily treatment by IPDE 5 on the LUTS secondary to BPH among patients with or without ED. MATERIALS AND METHODS we searched Medline for the peer-reviewed articles in English published, pertaining to findings of potential interest supporting a role of IPDE5 in LUTS due to BHP. The keywords used were: benign prostatic hyperplasia; cyclic nucleotide phosphodiesterase type 5; lower urinary tract symptoms; erectile dysfunction. RESULTS Generally, daily treatment with IPDE 5 improves the LUTS secondary to BPH as well as in both the storage and voiding domains of the international prostate symptom score (IPPS) and in quality of life questionnaire. It was not observed adverse events. CONCLUSION The first results of the use of IPDE 5 in the LUTS treatment secondary to the HBP seem promising. However, a direct comparison of efficacy of IPDE 5 and alpha-blockers or 5-alpha-reductase inhibitors is not yet available. The mechanism(s) of action(s) of these compounds in this indication remain difficult to affirm even if new hypotheses can be formulated.
Collapse
|
10
|
Shah NB, Wittich CM. 82-year-old man with bilateral leg swelling. Mayo Clin Proc 2010; 85:859-62. [PMID: 20810796 PMCID: PMC2931621 DOI: 10.4065/mcp.2009.0654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Neel B. Shah
- Resident in Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic, Rochester, MN
| | - Christopher M. Wittich
- Adviser to resident and Consultant in General Internal Medicine, Mayo Clinic, Rochester, MN
- Individual reprints of this article are not available. Address correspondence to Christopher M. Wittich, MD, PharmD, Division of General Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905 ()
| |
Collapse
|
11
|
Affiliation(s)
- Thomas J Beckman
- Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
| | | |
Collapse
|
12
|
Tamler R, Mechanick JI. Dietary supplements and nutraceuticals in the management of andrologic disorders. Endocrinol Metab Clin North Am 2007; 36:533-52. [PMID: 17543734 DOI: 10.1016/j.ecl.2007.03.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Dietary supplements and nutraceuticals are commonly used by men with erectile dysfunction, decreased libido, BPH, and concerns about developing prostate cancer. Many preparations do not contain the advertised dosages of the active ingredient or are contaminated. Dietary supplements and nutraceuticals, particularly those addressing erectile dysfunction and libido, need to undergo rigorous testing before they can be wholeheartedly recommended.
Collapse
Affiliation(s)
- Ronald Tamler
- Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1055, New York, NY 10029, USA.
| | | |
Collapse
|
13
|
Abstract
Prostate cancer is the most prevalent newly diagnosed noncutaneous malignancy in men. With the continued use of prostate-specific antigen screening, there has been a dramatic rise in the number of prostate biopsied performed. Transrectal ultrasonography (TRUS) is an essential tool used for detecting prostate pathology and performing prostate biopsies. This article review the indications and principles of TRUS of the prostate, the technique of TRUS, and controversies pertaining to prostate core biopsy.
Collapse
Affiliation(s)
- Judd Boczko
- Department of Urology, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
| | | | | |
Collapse
|
14
|
Abstract
Assessment and treatment of benign prostatic hyperplasia, or enlarged prostate, has evolved considerably in recent years; clear evidence has accumulated for the progression of disease over time, the association between disease progression and negative outcomes, and the potential for medical management of this condition. Commensurate with the long-term preventive role of primary care, efforts can and should be made to treat the underlying condition of enlarged prostate as well as to manage the symptoms short-term. This review outlines evaluation of men presenting with lower urinary tract symptoms, examines the challenges for medical treatment and suggests how treatment choice can address these challenges.
Collapse
Affiliation(s)
- M J Naslund
- Division of Urology, University of Maryland School of Medicine, Baltimore, MD, USA.
| | | | | |
Collapse
|
15
|
Capodice JL, Katz AE. What patients take without telling you: holistic approach for BPH. World J Urol 2006; 24:378-82. [PMID: 16738853 DOI: 10.1007/s00345-006-0093-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2006] [Accepted: 04/11/2006] [Indexed: 11/27/2022] Open
Abstract
The use of botanicals and supplements have markedly increased in men that are seeking increased protection against the potential onset and symptomatic relief of lower urinary tract symptoms that are commonly experienced with benign prostatic hyperplasia (BPH). While this implies a positive trend and considers that men are taking a more active role in health and prevention, dialog between the patient and the clinician is often deficient. This may be due to a number of factors including both the patients' inability to report about the use of certain agents and the clinicians' inability to ask. Moreover, the sense that natural agents may lack side effects coupled with ineffective communication between the doctor and patient could result in potential adverse interactions. We have performed a comprehensive search of articles published from 1990 to 2005 using the Medline databases in order examine clinical data on the most commonly researched herbs for BPH. We provide a brief update on the state of the research.
Collapse
Affiliation(s)
- Jillian L Capodice
- Center for Holistic Urology, Department of Urology, Columbia University Medical Center, New York, NY 10032, USA.
| | | |
Collapse
|
16
|
Federman DG. Finasteride: middle-age cure-all for alopecia and benign prostatic hyperplasia? Mayo Clin Proc 2006; 81:267; author reply 267-8. [PMID: 16471089 DOI: 10.4065/81.2.267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|